– Granted US patent provides market exclusivity until 2032
Leiden, The Netherlands, April 19, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced it has been granted a US patent on its AMPLIVANT® technology and compounds (patent no. 9,314,521). The patent ensures market protection in the United States until 2032 and covers the compounds, either as a stand-alone substance or in combination with antigenic peptides, nucleic acids or antibodies. The patent also covers the process for preparing the compounds.
ISA’s AMPLIVANT® technology provides an adjuvant that has been demonstrated
– ISA101 clinically effective against HPV-induced vulvar / vaginal lesions and cervical cancer
– Optimum immunotherapy window in cancer identified
Leiden, The Netherlands, April 14, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has announced the publication of two peer-reviewed research manuscripts demonstrating the clinical efficacy of its lead product ISA101 in treating high-grade vulvar intraepithelial neoplasia (VIN), and synergy with chemotherapy in cervical cancer. In cervical cancer, the optimum window for treatment with ISA101 starts two weeks after the second chemotherapy cycle has been completed. The multi-center research was conducted in close collaboration with Leiden University Medical Center (LUMC). Publications
– Targeting and Activating Dendritic Cells is the Key to Success
Leiden, The Netherlands, March 11, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has announced the publication of a review of cancer immunotherapies in Nature Reviews Cancer  that outlines strategies to overcome immune evasion by tumors. The publication was co-authored by a team of researchers from Leiden University Medical Center (LUMC) and ISA Pharmaceutical’s’ CSO Kees Melief.
Cancer immunotherapies have a mixed track record. While challenging the immune system via tumor antigens by raising tumor-specific T cells is successful in most cases, this strategy often does not cause T
– Seasoned executive brings over twenty years of commercial biotech and pharma experience
Leiden, The Netherlands, January 5, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that Gerben Moolhuizen has been appointed as the company´s Chief Business Development Officer (CBO).
Gerben Moolhuizen has over twenty years of experience in the pharmaceutical and biotechnology industry in various roles covering business development, product development and general management. His experience spans very diverse fields covering a broad array of technical areas (biopharmaceuticals, small molecules, drug delivery, pharmaceutical development and manufacturing, diagnostics,